Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

CardioMetabolic Care

CardioMetabolic Care
An integrated approach to diagnosis and treatment
We combine our drugs for treating diabetes, cardiovascular diseases and thyroid disorders in one therapeutic area: CardioMetabolic Care.
In recent years, interrelationships between cardiovascular diseases, diabetes and thyroid disorders have been recognized and documented. We offers doctors and patients the opportunity to treat the often complex symptoms more effectively by taking an integrated approach to disease management.

Diabetes and heart disease are closely linked; studies show that diabetes is frequently combined with other cardiovascular risk factors such as high blood pressure, obesity and lipid disorders, a clustering of risk factors known as metabolic syndrome. Thyroid disorders are closely associated with both diabetes and cardiovascular disease. In patients with type 2 diabetes, thyroid disorders are two to five times more frequent than among the general population. Heart muscle cells contain receptors for thyroid hormones, so cardiac function is influenced by too many or too few thyroid hormones.

Cardiovascular diseases continue to be the most frequent cause of death in industrialized countries. We offer an extensive range of therapeutic options to treat these conditions, along with drugs for the treatment of glucose metabolism and thyroid disorders. Our company is among the leading manufacturers of oral antidiabetic agents for the treatment of type 2 diabetes, formerly referred to as “adult-onset diabetes”.

We have a longstanding commitment to the treatment of thyroid diseases, dating back to 1894 when its first thyroid medicine was launched. Today the company markets Euthyrox® (levothyroxine sodium) and Novothyral® (levothyroxine sodium, liothyronine sodium) for the treatment of hypothyroidism, Thyrozol® (thiamazole) for hyperthyroidism, Jodid™ (potassium iodide) for iodine deficiency (a cause of enlargement of the thyroid gland leading to goiter) and Jodthyrox® (levothyroxine sodium and potassium iodide) for the treatment of goiter.


The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.

US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.


Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.